Healing

TB-500

Clinical Trials
Share:

A synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). NOT the same as TB-4 - TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.

Mechanism of Action

TB-500 is derived from the active region of the full Thymosin Beta-4 protein. It promotes cell migration by binding to and sequestering actin, a protein essential for cell movement. It upregulates actin expression, promotes angiogenesis, reduces inflammation, and facilitates hair follicle stem cell migration for wound healing.

Research Summary

Research shows significant wound healing acceleration, cardiac tissue repair after heart attack in animal models, and anti-inflammatory effects. Studies demonstrate improved recovery from dermal wounds and muscle injuries. Human clinical trials ongoing for wound healing applications.

Clinical Status:Clinical trials - Phase II trials for wound healing
Trial Progress:Phase II
Pre
I
II
III
IV
FDA

Research Protocols

Human Trials·Human studies conducted, not FDA approved

Note: Doses observed in research studies

Duration

4-6 weeks loading, then maintenance

Administration

Subcutaneous or intramuscular injection

Timing & Administration

Healing

As a Healing peptide: Morning or evening is the recommended administration time.

Best Time to Take

Morning or evening

2-3 times per week

Food Recommendation

either

Why This Timing?

Based on mechanism of action: TB-500 has a long half-life, so timing is flexible. Consistency matters more than specific time of day.

Timing recommendations are based on pharmacological principles and mechanism of action, not dedicated clinical trials on administration timing. Most peptide studies focus on efficacy rather than optimal timing. Consult a healthcare provider for personalized guidance.

Side Effects & Considerations

  • Generally well-tolerated
  • Injection site reactions
  • Headache
  • Fatigue
  • Nausea
  • May trigger histamine release - use caution with MCAS or histamine sensitivity
  • Theoretical concern for cancer cell motility
  • Contraindicated with active cancer
  • Limited long-term safety data

References

Want updates on TB-500 research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Educational Information Only

This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.